Podcast

Alegent Health: Type 2 Diabetes

John Harris, MD, talks about the risks associated with diabetes and the steps patients can take to protect themselves.

In this Alegent Health Podcast, John Harris, MD, talks about the risks associated with diabetes and the steps patients can take to protect themselves and their family members.

Click here to access this third party resource.

Related Videos
Pranav Garimella, MBBS, MPH | Credit: GlobalNewsWire
Advocating for Race-Neutral Approach to Pulmonary Function Testing with Meredith McCormack, MD, and Loretta Que, MD
Skin of Color Savvy: The Art and Science of Treating Patients of Color
Looking at This Year in Pulmonology: A Lungcast 2024 Recap
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Related Content
FDA black and white logo | Credit: US Food and Drug Administration
January 28th 2025

FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease

Abigail Brooks, MA
Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D
January 31st 2025

Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use | Image Credit: University of Maryland
January 24th 2025

Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use

Connor Iapoce
Ep 16: A Look at Qlosi for Presbyopia with Elad Kedar, MBA| Image Credit: HCPLive
January 28th 2025

New Insight: A Look at Qlosi for Presbyopia with Elad Kedar, MBA

Veeral Sheth, MD, MBA, FASRS, FACS Connor Iapoce
Semaglutide 7.2 mg Exhibits 20.7% Weight Loss in Phase 3b STEP UP Trial | Image Credit: Novo Nordisk
January 17th 2025

Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial

Connor Iapoce
HHS Targets 15 Drugs for Medicare Part D Negotiations, Including Semaglutide | Image Credit: HHS
January 17th 2025

HHS Targets 15 Drugs for Medicare Part D Negotiations, Including Semaglutide

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.